INSIGHTS ON CELL & GENE THERAPY LOGISTICS

• Managing Supply Disruptions In ATIMP Clinical Trials

  ATIMP trials leave little room for error. Learn how teams use contingency planning, real-time data, and AI to prevent supply disruptions.

• 5 Operational Gaps To Avoid CGT Patient Risks

  Examine five critical supply chain gaps in cell and gene therapy logistics that put patients at risk, from invisible operational burdens to reactive monitoring and fragmented coordination strategies.

• Increasing Patient Safety: Risk Assessment For Small Volume Fluid Management

  Explore the risk factors in small-volume fluid management, learn where manual processes introduce variability, and find out how closed, pump-driven single-use systems can improve accuracy and consistency.

• Addressing The Acetonitrile Supply By Implementing Strategies

  Rising acetonitrile demand threatens supply chains; recovery and reuse methods using evaporation and crystallization produce high‑purity solvent, reducing costs, waste, and reliance on fresh supply.

• An Innovative, Modular Approach To Flexible Supply Chain Management

  Learn how modular strategies, global coordination, and data-driven decisions help maintain continuity, compliance, and speed amid constant uncertainty.

• Accelerated Delivery Of Manufacturing Capacity

  When demand spikes unexpectedly, standardized facility design and aligned equipment strategies can dramatically shorten expansion timelines. See how to reduce uncertainty across procurement.

• Reducing Inventory Errors In Clinical Trials

  Can a digital double-check save your trial from data errors? How does verifying shipments at receipt slash inventory mistakes? Learn to protect protocol integrity and patient safety.

• 9 Logistics And Distribution Recommendations For CGTs

  Cell and gene therapy commercialization requires tailored logistics strategies. Explore nine recommendations covering site readiness, reimbursement gaps, packaging, testing, and coordination.

• Inside March Biosciences' CD5-Targeting CAR-T Approach

  Fratricide is one of the key reasons T-cell therapies targeting T-cell malignancies have faltered. March's approach aims to solve that with its MB-105 candidate.

• Accelerate Your Trials With An End‑To‑End Supply Chain Model

  An end-to-end supply chain model helps clinical trials move faster while maintaining visibility, control, and risk management across complex, temperature‑sensitive, and global operations.